+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Doxorubicin Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 140 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797894
The global doxorubicin market size attained a value of USD 1218 million in 2022. The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2023-2031 to attain a value of USD 2128.8 million by 2031.

Doxorubicin Market: Introduction

Doxorubicin, also known as Adriamycin or hydroxydaunorubicin, is a chemotherapy drug belonging to the class of anthracycline antibiotics. It is derived from the Streptomyces peucetius bacterium and is known for its red colour. Doxorubicin is used primarily in the treatment of a wide range of cancers, including breast cancer, ovarian cancer, lung cancer, stomach cancer, thyroid cancer, bladder cancer, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphomas.

The drug works by intercalating into DNA, which prevents the replication of cancer cells and eventually leads to cell death. Doxorubicin also inhibits the enzyme topoisomerase II, which is involved in DNA replication and transcription, further contributing to the drug's anticancer effects.

The benefits of doxorubicin include:

1. Broad-spectrum activity: It is effective against a wide range of cancer types, making it a valuable treatment option for many patients.
2. Combination therapy: Doxorubicin is often used in combination with other chemotherapy drugs, enhancing their effectiveness and improving treatment outcomes.
3. Proven effectiveness: Doxorubicin has a long history of use in cancer treatment and has been proven effective in various clinical trials and studies.

However, doxorubicin has several side effects and risks, including heart damage (cardiotoxicity), bone marrow suppression, nausea, vomiting, hair loss, and mouth sores. The risk of cardiotoxicity increases with cumulative doses, so the total amount of doxorubicin a patient can receive during their lifetime is limited. Doctors and healthcare providers closely monitor patients receiving doxorubicin to manage side effects and minimize risks.

Doxorubicin Market Segmentations

The market can be categorised into application, distribution channel, and regions.

Doxorubicin Market Breakup by Application

  • Ovarian Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Leukaemia
  • Bone Sarcoma
  • Breast Cancer
  • Endometrial Cancer
  • Gastric Cancer
  • Liver Cancer
  • Kidney Cancer
  • Other Cancers

Doxorubicin Market Breakup by Distribution Channel

  • Market Overview
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Doxorubicin Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Doxorubicin Market Scenario

Doxorubicin is a chemotherapy drug that is used to treat various types of cancer, including breast cancer, ovarian cancer, and bladder cancer, among others. It works by inhibiting the growth of cancer cells and preventing them from dividing and spreading throughout the body. Doxorubicin is typically administered intravenously, and it is often used in combination with other chemotherapy drugs.

Industry Trends
The global market for doxorubicin is expected to continue to grow in the coming years, driven by an increasing incidence of cancer and a growing demand for effective treatments. In addition, the development of new formulations and delivery methods for doxorubicin is expected to further drive market growth. For example, liposomal doxorubicin, a type of doxorubicin that is encapsulated in a lipid membrane, has been shown to be more effective and less toxic than conventional doxorubicin in some cases.

However, the market for doxorubicin is also facing challenges, including the high cost of treatment and the potential for serious side effects. In addition, the emergence of alternative therapies, such as immunotherapy and targeted therapies, may limit the growth of the doxorubicin market in the coming years. Nevertheless, doxorubicin remains an important and widely used chemotherapy drug, and its continued development and use will play an important role in the fight against cancer.

Key Players in the Global Doxorubicin Market

The report gives an in-depth analysis of the key players involved in the doxorubicin market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Pfizer Inc
  • Sun Pharmaceutical Industries Limited
  • Cipla, Inc
  • Cadila Pharmaceuticals Ltd
  • SRS PHARMACEUTICALS PVT. LTD.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Doxorubicin Market Overview
3.1 Global Doxorubicin Market Historical Value (2016-2022)
3.2 Global Doxorubicin Market Forecast Value (2023-2031)
4 Global Doxorubicin Market Landscape
4.1 Global Doxorubicin Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Doxorubicin Product Landscape
4.2.1 Analysis by Doxorubicin Application
4.2.2 Analysis by Distribution Channel
5 Global Doxorubicin Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Doxorubicin Market Segmentation
6.1 Global Doxorubicin Market by Application
6.1.1 Market Overview
6.1.2 Ovarian Cancer
6.1.3 Multiple Myeloma
6.1.4 Kaposi Sarcoma
6.1.5 Leukaemia
6.1.6 Bone Sarcoma
6.1.7 Breast Cancer
6.1.8 Endometrial Cancer
6.1.9 Gastric Cancer
6.1.10 Liver Cancer
6.1.11 Kidney Cancer
6.1.12 Other Cancers
6.2 Global Doxorubicin Market by Distribution Channel
6.2.1 Market Overview
6.2.2 Hospital Pharmacy
6.2.3 Retail Pharmacy
6.2.4 Online Pharmacy
6.3 Global Doxorubicin Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Doxorubicin Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Doxorubicin Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Doxorubicin Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Doxorubicin Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Doxorubicin Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Pfizer Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Sun Pharmaceutical Industries Limited
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Cipla, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Cadila Pharmaceuticals Ltd.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 SRS PHARMACEUTICALS PVT. LTD.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
18 Global Doxorubicin Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket

Companies Mentioned

  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Cipla, Inc.
  • Cadila Pharmaceuticals Ltd.

Methodology

Loading
LOADING...

Table Information